Chester County News and Community Website
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) will present clinical results from its QTORIN™ rapamycin program at the ISSVA World Congress 2026 in Philadelphia, with data from Phase 3 …
Palvella to Present QTORIN Study Data at ISSVA 2026 Conference Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) recently appointed John D. Doux, M.D., M.B.A., to its board of directors as the company advances its pipeline of treatments for rare …
Palvella Therapeutics Appoints John D. Doux to Board Read More WAYNE, PA — Palvella Therapeutics Inc. (Nasdaq: PVLA) has appointed Kent Taylor as senior vice president of sales to lead its U.S. commercial organization ahead of a potential product launch.
Palvella Appoints Kent Taylor as Senior Vice President of Sales Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) recently reported its full-year 2025 financial results and outlined progress across its QTORIN drug development pipeline, including plans to submit a new …
Palvella Reports 2025 Results, Advances QTORIN Drug Pipeline Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced the publication of a review article in the Journal of Vascular Anomalies examining clinical differences and treatment approaches for microcystic and …
Palvella Publishes Review on Lymphatic Malformations in Medical Journal Read More WAYNE, PA — Palvella Therapeutics Inc. (Nasdaq: PVLA) recently appointed Jennifer J. McDonough as senior vice president of market access and patient services as the company prepares for a potential …
Palvella Appoints McDonough as SVP of Market Access, Patient Services Read More WAYNE, PA — Palvella Therapeutics Inc. (Nasdaq: PVLA) said the European Patent Office has granted a patent covering its lead product candidate QTORIN 3.9% rapamycin gel, extending intellectual property protection …
European Patent Office Grants Palvella Patent for QTORIN Rapamycin Read More WAYNE, PA — Palvella Therapeutics Inc. (Nasdaq: PVLA) announced the launch of “BEYOND mLM,” a disease awareness campaign and website designed to provide educational resources for patients, caregivers, and healthcare …
Palvella Therapeutics Launches Awareness Campaign for Rare Lymphatic Disease Read More WAYNE, PA — Palvella Therapeutics Inc. (Nasdaq: PVLA) said it achieved the primary and all secondary endpoints in a Phase 3 trial of QTORIN 3.9% rapamycin gel for microcystic lymphatic …
Palvella Reports Phase 3 Success for QTORIN in Rare Skin Disorder Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) said a newly published systematic review strengthens the scientific case for using topical statins to treat porokeratosis, a rare and progressive genetic …
Topical Statins Show Promise for Rare Skin Disease in New Review Read More